From a histopathological perspective, the patient’s immunophenotypic profile, positive for CD20, CD30, BCL6, MUM1, and BCL2, with a high proliferation index (Ki-67: 95%), is indicative of an activated B-cell subtype of DLBCL. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.